You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
眾生藥業(002317.SZ):全資子公司獲得羧甲司坦口服溶液藥品註冊證書
格隆匯 10-17 18:47

格隆匯10月17日丨眾生藥業(002317.SZ)公佈,公司全資子公司廣東華南藥業集團有限公司於近日收到國家藥品監督管理局核准簽發的羧甲司坦口服溶液《藥品註冊證書》。

羧甲司坦為臨牀常用黏液調節劑,一方面能溶解已經分泌的黏液,通過藥物結構中的巰基與黏液中黏蛋白的二硫鍵相互作用,裂解黏蛋白;另一方面能調節黏液分泌,使低黏度的唾液黏蛋白分泌增加,高黏度的巖藻黏蛋白產生減少,因而使痰液的黏稠性降低而易於咳出。羧甲司坦口服溶液用於治療慢性支氣管炎、支氣管哮喘等疾病引起的痰液黏稠、咳痰困難患者,為國家基本藥物目錄和醫保目錄乙類藥物。

根據米內網數據庫顯示,羧甲司坦口服溶液2020至2022年在中國城市公立醫院及中國城市實體藥店的銷售總額合計為人民幣31,025萬元,53,715萬元,56,544萬元。

公司本次獲批的羧甲司坦口服溶液(10ml:0.5g)是繼2023年7月獲批上市【羧甲司坦口服溶液(100ml:2g)】後的又一規格無糖型產品,該產品以化學藥品註冊分類3類獲批上市,標誌着此產品視同通過化學仿製藥一致性評價。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account